Clinical Trial Update: Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov entry reports a Phase II study of bortezomib (PS-341) in patients with previously treated advanced urothelial tract transitional cell ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Bladder
• Transitional Cell Carcinoma of the Renal Pelvis
• Transitional Cell Carcinoma of the Ureter

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer | Phase 2 | Status: COMPLETED